Related Experiment Video
Updated: Apr 19, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Functional interpretation of metabolomics data as a new method for predicting long-term side effects: treatment of
Seul Ji Lee1, Sung-il Woo2, Soo Hyun Ahn3
1College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea.
Insights
Topical calcineurin inhibitors (TCIs) show similar efficacy and superior safety for treating atopic dermatitis in infants compared to desonide. Metabolomics effectively predicted long-term side effects in this vulnerable population.
Area of Science:
- Dermatology
- Pediatrics
- Pharmacology
- Metabolomics
Background:
- Topical steroids are standard for atopic dermatitis (AD) but carry risks in children.
- Topical calcineurin inhibitors (TCIs) offer a steroid-free alternative but have age restrictions due to safety concerns.
- Evaluating TCI efficacy and safety in infants under two years is crucial.
Purpose of the Study:
- To assess the efficacy and safety of 1% pimecrolimus cream versus 0.05% desonide cream in children under two years with AD.
- To utilize urinary metabolomics for predicting potential long-term adverse effects.
Main Methods:
- A randomized, double-blind trial comparing 1% pimecrolimus cream and 0.05% desonide cream.
- Inclusion of children under two years of age with atopic dermatitis.
- Application of urinary metabolomics for predictive toxicity analysis.
Main Results:
- 1% pimecrolimus cream demonstrated comparable efficacy to 0.05% desonide cream.
- 1% pimecrolimus cream exhibited excellent safety profiles in the studied pediatric population.
- Metabolomics successfully predicted long-term medication side effects using short-term clinical data.
Conclusions:
- 1% pimecrolimus cream is a safe and effective secondary treatment option for atopic dermatitis in infants.
- Urinary metabolomics provides a viable method for predicting long-term drug toxicity in clinical settings.
- This study establishes a foundation for future research on predicting medication-related systemic reactions.
Abstract:
Topical steroids are used for the treatment of primary atopic dermatitis (AD); however, their associated risk of serious complications is great due to the presence of vulnerable lesions in young children with AD. Topical calcineurin inhibitors (TCIs) are steroid-free, anti-inflammatory agents used for topical AD therapy. However, their use is prohibited in infants <2 years of age because of their carcinogenic potential. We conducted a randomized, double-blind trial to evaluate the efficacy of TCIs as a secondary AD treatment for children <2 years of age by comparing 1% pimecrolimus cream with 0.05% desonide cream. We performed urinary metabolomics to predict long-term side effects. The 1% pimecrolimus cream displayed similar efficacy and exceptional safety compared with the 0.05% desonide cream. Metabolomics-based long-term toxicity tests effectively predicted long-term side effects using short-term clinical models. This applicable method for the functional interpretation of metabolomics data sets the foundation for future studies involving the prediction of the toxicity and systemic reactions caused by long-term medication administration.
